125 filings
Page 5 of 7
6-K
ube4jb3ao9x7yw62
26 Sep 19
Current report (foreign)
12:31pm
6-K
sojnnrbit
13 Sep 19
Current report (foreign)
1:24pm
6-K
ff3ku 97huzj
13 Sep 19
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
12:02pm
6-K
ppcfw
30 Aug 19
Current report (foreign)
8:28am
6-K
6mu h06jclejhl
22 Aug 19
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
6:05am
6-K
kd0o7b5
21 Aug 19
Capital Increase in Genmab as a Result of Employee Warrant Exercise
1:01pm
6-K
rf7c6vje0uzq
14 Aug 19
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
12:00am
6-K
570l qrd627hqhi7m1f
23 Jul 19
Current report (foreign)
11:48am
6-K
yvtnd
22 Jul 19
Current report (foreign)
11:35am
424B4
vgaxo1de55 zj24l
19 Jul 19
Prospectus supplement with pricing info
12:00am
F-6EF
j85c8qhe
18 Jul 19
Automatic registration for ADRs (foreign)
9:30am
EFFECT
gf04 o0pa5
18 Jul 19
Notice of effectiveness
12:15am
F-1MEF
qlbdexxdugpp9f f8jp
17 Jul 19
Registration statement to add securities to prior F-1 registration
7:55pm
S-8
0qeexbn8oz
17 Jul 19
Registration of securities for employees
5:24pm
FWP
1y9lrhq3hs t4
16 Jul 19
Free writing prospectus
8:54am
F-1/A
nnxfgo2
16 Jul 19
Registration statement (foreign) (amended)
8:05am
F-6 POS
uteqsp
15 Jul 19
Automatic registration for ADRs (post-effective amendment, foreign)
5:01pm
CERT
246agj
15 Jul 19
Certification of approval for exchange listing
2:37pm
8-A12B
kbd0jef9nr z8egqzmwy
12 Jul 19
Registration of securities on exchange
4:52pm
FWP
otxj7p8xe5wsjb2 2qnq
12 Jul 19
Free writing prospectus
11:53am